



BONE CANCER RESEARCH TRUST.

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

BONE CANCER RESEARCH TRUST
Charity Reg. No. 1113276

**TRUSTEES' REPORT
AND
FINANCIAL STATEMENTS**

FOR THE YEAR ENDED 30 JUNE 2010

CONTENTS:	Pages 2 - 3
1.0 Legal and Administrative Information	Pages 4 - 7
2.0 OBJECTIVES AND ACTIVITIES	Pages 8 - 9
2.1 Grant Making Policy	
3.0 STRUCTURE, GOVERNANCE AND MANAGEMENT for the year 1st. July 2009 to 30th. June 2010	Pages 9 - 12
3.1 Trustees	
3.2 Scientific Advisory Panel (SAP)	
3.3 Related Parties	
3.4 Risk Management	
3.5 Trust Patrons	
3.6 Enlargement of the Trust's own office facilities	
3.7 Staff	
3.8 Voluntary Workers	
3.9 Human Resources Consultancy	
3.10 Professional Advisors	
3.11 General, Designated and Restricted Fund Accounts	
4.0 LINKS WITH OTHER ORGANISATIONS	Pages 12 - 13
4.1 National Alliance of Childhood Cancer Parent Organisations (NACCPO)	
4.2 British Sarcoma Group – 5 th . Annual Conference, London	
4.3 Sarcoma UK	
4.4 National Institute for Health and Clinical Excellence (NICE)	
4.5 National Sarcoma Register Steering Group	
4.6 Teenage Cancer Trust (TCT)	
5.0 ACHIEVEMENTS AND PERFORMANCE	Pages 13 – 18
5.1 Research Applications and Grants	
5.2 Promotional Activity	
5.3 Autumn 2009 and Spring 2010 BCRT Newsletters	
5.4 BCRT in Ireland	
5.5 Some of the many Fundraising Events in 2009/10	
5.6 BCRT Merchandising	
5.7 Development of the Website and other electronic forms of communication	
5.8 Looking to the Future	
6.0 FINANCIAL REVIEW	Page 19
6.1 Principle Funding Sources	
6.2 Charity Reserves	
6.3 Investment Policy	
6.4 Donations	
7.0 PLANS FOR FUTURE PERIODS	Pages 19 – 20
8.0 FINANCIAL STATEMENT	Page 21
9.0 INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BONE CANCER RESEARCH TRUST	Page 22
10.0 STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30TH. JUNE 2010	Page 23

11.0	BALANCE SHEET AT 30th. JUNE 2010	Page 24
12.0	NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED 30TH. JUNE 2010	Pages 25 – 35
	1. Accounting Policies	
	2. Grants and Donations	
	3. Costs of Generating Funds	
	4. Charitable Activities	
	5. Governance Costs	
	6. Trustee and Staff Costs	
	7. Fixed Assets	
	8. Liabilities: Amounts falling due within One Year	
	9. Liabilities: Amounts falling due after One Year	
	10. Dedicated Funds	
	11. Restricted Funds	
	APPENDIX A : How the Bone Cancer Research Trust came into being	Pages 36 – 37
	APPENDIX B : Initial Structure, Governance and Management	Pages 38 – 39
	B.1 Governing Document	
	B.2 Organisational Structure	
	B.3 First Trustees	
	B.4 Scientific Advisory Panel (SAP)	
	B.5 Recruitment and Appointment of Trustees	
	APPENDIX C : Pre-Trust Foundation Research Projects	Page 40
	Appendix D : An update on the Trustees of the Bone Cancer Research Trust	Page 41

1.0 LEGAL AND ADMINISTRATIVE INFORMATION:

Date of Trust Deed: - 15th. December 2005.

Charity Registration Details:- Registered Number 1113276, registered on 14th. March 2006 in England.

Working Names:- BCRT : bcrt : Bone Cancer Research : BCR : Team Bones.

Trustees who served during the year 1st. July 2009 to 30th. June 2010.

Nicholas Darren Bones (*resigned 26 June 2010*)

John Dealey

Fiona Marie Foley

Michael Brian Palmer Francis (Chairman)

Craig Hamilton Gerrand MB ChB FRCS (Edin) MD MBA (*appointed 26 June 2010*)

Patrick Michael Hardman

Laura Elizabeth Horton (*appointed 26 June 2010*)

Sally Hurst (*resigned 26 June 2010*)

Ian John Lewis MB ChB FRCP FRCPCH

Roger Paul (Deputy Chairman)

Gillian Elizabeth Pilcher

Patricia Smith

Clerk to the Trustees : Rosalyn M. Francis MA.

Legal and Administrative Information (*continued*)

Scientific Advisory Panel:-

Professor I J. Lewis MB ChB FRCP FRCPCH.

Consultant Paediatric & Adolescent Oncologist, St. James's University Hospital, Leeds.

Mr. C. H. Gerrand MB ChB FRCS (Edin) MD MBA

Consultant Orthopaedic Surgeon, Freeman Hospital, Newcastle-upon-Tyne.

Honorary Clinical Senior Lecturer, Northern Institute for Cancer Research, University of Newcastle.

Mr. R. Grimer MB BS FRCS (Eng) FRCS (Edin) Orth.

Consultant Orthopaedic Surgeon, Royal Orthopaedic Hospital, Birmingham.

Dr. J. Whelan MD MB BS FRCP.

Consultant Medical Oncologist and Clinical Director of Cancer Services,

Meyerstein Institute of Oncology, University College Hospital, London.

Registered Office & Fundraising and Administration Centre:-

Suite 7, Gledhow Mount Mansion,

Roxholme Grove, Leeds, LS7 4JJ.

Telephone: 0113 262 1852. Fax: 0113 262 5391.

Email: info@bonecancerresearch.org.uk Web Address: www.bcrtr.org.uk

Trustee Correspondence:-

Clerk to the Trustees,

Suite 7, Gledhow Mount Mansion, Roxholme Grove, Leeds, LS7 4JJ.

Telephone: 01904 448696 (*Direct Line*).

Independent Examiner:-

C. J. Darwin ACA,
Messrs. Thomas Coombs & Son, Chartered Accountants,
29, Clarendon Road, Leeds, LS2 9PG.

Solicitors:-

Brooke North LLP,
Crown House, Great George Street, Leeds, LS1 3BR.

Bankers:-

The Co-operative Bank,
PO Box 250, Delf House, Skelmersdale, WN8 6WT.

CAF Bank Ltd.,
25, Kings Hill Avenue, Kings Hill, West Malling, NE19 4JQ.

Human Resource Consultants:-

Abacus Hr Ltd.,
Abacus House, 7 Summerlea Court, Herriard, Basingstoke, Hampshire, RG25 2PN.

BCRT Staff:-

Head of Fundraising:-

David Fisher BSc.

Telephone : 0113 2621853. Fax: 0113 2625391.

Email : david.fisher@bcrt.org.uk

Administrator:-

Kate Connor BA(Hons).

Telephone : 0113 2621853. Fax: 0113 2625391.

Email : kate.connor@bcrt.org.uk

Marketing Officer:-

Lauren Heslop BA(Hons) PGDipM MCIM Chartered Marketer.

Telephone : 0113 2621853. Fax: 0113 2625391. Mobile : 07528 846338.

Email : lauren.heslop@bcrt.org.uk

Accounting Technician:-

Maggy Barnes FMAAT.

Telephone : 0113 2621853. Fax: 0113 2625391.

Email : maggy.barnes@bcrt.org.uk

Information Officer:-

Dr. John Newby BSc(Hons) PhD.

Telephone : 0113 2621853. Fax: 0113 2625391.

Email : john.newby@bcrt.org.uk

The Trustees present their Annual Report and Financial Statements for the year ended 30th. June 2010.

The comparative period covers 1st. July 2008 to 30th. June 2009.

As an opening statement, the Trustees wish to record their observation that the composition of the Trust is changing in that the baseline membership of the Trust is diminishing from being a bereaved family and friends fund raising charity, into a more inclusive and coherent organisation where present and former patients of Primary Bone Cancers are playing an increasingly important part. Despite the restrictions of data protection legislation, this is being achieved through positive wishes of present and former patients to come to the Trust and be involved in its vision.

The Trustees also acknowledge the considerable support and guidance being given freely by many Medical Practitioners and Professionals, which is opening doors into many areas hitherto closed.

The Trustees are delighted to report that, as at the end of the Financial Year to 30th June 2010, over £1,150,000 has been raised since the Trust became an organisation in December 2005 and a Registered Charity in March 2006.

In this Report, the Trustees have sought to provide clear details about the activities undertaken by the Charity to further its charitable purposes for the public benefit.

The Trustees believe that they have complied with the duty set out in section 4 of the Charities Act 2006, and have paid due regard to public benefit guidance published by the Charity Commission.

2.0 OBJECTIVES AND ACTIVITIES FOR PUBLIC BENEFIT:

The Trust Deed states that the Trustees must apply the income in furthering the relief of sickness generally and in particular, but not so as to limit the generality, the foregoing:-

Promoting research into the causes and treatment of Primary Bone Cancer in young people, and in particular of Osteosarcoma and Ewing's Sarcoma, and publishing the useful results thereof;

Providing counselling, support and information services for persons suffering from Primary Bone Cancer, and their families.

2.1 Grant Making Policy:

One of the basic aims of the Bone Cancer Research Trust is to promote research into Primary Bone Cancers and particularly osteosarcoma and Ewing's sarcoma. The Charity is interested in any research that can improve outcomes for patients so will consider research applications from a wide variety of perspectives. These include biological, translational, clinical, epidemiological, psycho-social and health services research.

The Charity is particularly interested in providing "pump-priming" grants that might initiate or support work that could lead to more substantial applications to national or international funders. It is intended that there will be up to two calls for grant applications each year. Applications for grants should be submitted, using the downloadable form on the Charity's website – info@bcrt.org.uk. This can be sent either electronically to research@bonecancerresearch.org.uk or six copies of the form can be posted to the Charity's Fundraising and Administration Office (fao Mrs. Kate Connor). Applicants should be expected to receive notification of the outcome of the round within 3 months of the closing date for applications.

BCRT now has National Institute for Health Research Clinical Research Network (NIHR CRN) Partner status which will ensure that studies funded by BCRT will be eligible for inclusion in the Portfolio (including other partner organisations). This will allow our research projects to have access to clinical infrastructure/NHS Service Support through the NIHR Clinical Research Networks.

Initially, the Trustees will consider bids of any sum up to £30,000.

Applications received by the Trust are forwarded to the Scientific Advisory Panel (SAP) for assessment. The Charity insists on external peer review for all funding requests of £10,000 and above. Requests for sums less than this may be granted by the SAP and Trustees without formal external review. Each application for external review will be overseen by a Specialist Advisor with particular expertise who will recommend appropriate Reviewers. External Reviewers will be asked to confirm that there is no significant conflict of interest.

Each round of applications will be considered by the SAP, who will determine which applications are of sufficient quality to be funded, and rank them accordingly. They could choose to recommend all or none. Recommendations will then be considered by the Trustees, who have the final decision on funding. This will be determined by available funds, not the quality of research.

3.0 STRUCTURE, GOVERNANCE AND MANAGEMENT for the year 1st. July 2009 to 30th. June 2010:

3.1 Trustees:

Details of the Trustees who have served for the year 1st. July 2009 to 30th. June 2010 are listed on page 4.

The Trustees have met on 4 occasions –

26th. September 2009 ; 28th. November 2009;

6th. March 2010 : 26th. June 2010.

At the Annual General Meeting held on 6th. March 2010, Michael Francis was re-elected as Chairman. John Dealey, having retired as Deputy Chairman of Trustees, was replaced by unanimous vote by Roger Paul.

On the 26th. June 2010, resignations were received from Sally Hurst and Nick Bones. The Trustees expressed their heartfelt thanks for the not inconsiderable contribution that both these former osteosarcoma patients have made to the formation and development of the Trust.

On the same day, the Trustees appointed 2 replacement Trustees, Craig Hamilton Gerrard MB ChB FRCS(Edin) MD MBA, a Consultant Orthopaedic Surgeon, and Laura Elizabeth Horton, a former Ewing's sarcoma patient.

The Trustees will continue to seek other additional and helpful areas of expertise.

3.2 Scientific Advisory Panel (SAP):

Mr. Robert Grimer MB BS FRCS (Eng) FRCS (Edin) Orth., and Dr. Jeremy Whelan MD MB BS FRCP, continued as members of the SAP, under the Chairmanship of Professor Ian Lewis MB ChB FRCP FRCPCH. Craig Hamilton Gerrard MB ChB FRCS(Edin) MD MBA joins them, having been appointed a Trustee.

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

3.3 Related Parties:

Reflecting the formation of the Trust by a number of Founding Groups, some of the Trustees are connected to the income received by the Charity during the current and previous periods as detailed in Note 2 of the Financial Statements. The specific connections are:-

Trustee	Related Party
Gillian Pilcher	Anthony Pilcher Bone Cancer Trust. RCN 1099337.
John Dealey	Adam Dealey Foundation for Ewing's Sarcoma.
Fiona Foley	Blathnaid Foley Trust <i>(Republic of Ireland)</i>
Michael Francis	Guy Francis Bone Cancer Research Fund
Patrick Hardman	Christopher Hardman Osteosarcoma Research Fund. RCN 1111059
Patricia Smith	Family & Friends of Krystle Smith. <i>(Republic of Ireland)</i>

3.4 Risk Management:

The Trustees have examined the major strategic, business and operational risks which the Charity faces, and confirm that systems have been established to enable regular reports to be produced so that the necessary steps can be taken to lessen these risks.

3.5 Trust Patrons:

The Trustees are pleased to announce the acceptance by Mr. Nick Bones (former BCRT Trustee) and Professor Alan Craft, MD, FMedSci, PPRCPCH, as Patrons. Their expertise in their respective fields will greatly enhance the performance of the Trust.

Mr. Marc Woods continues to be a Patron, and the Trustees congratulate him on his being conferred an Honorary Doctorate from Middlesex University, and his appointment as an Ambassador for London 2012 Olympics and a Member of the British Paralympic Advisory Panel for London 2012 Games.

3.6 Enlargement of the Trust's own office facilities:

The move into larger offices has proved very beneficial, allowing for a separate Meeting Room, and space to have Volunteers assisting the employed Staff on occasions.

3.7 Staff:

During the year, Lauren Heslop BA(Hons), PGDipM, MCIM, Chartered Marketer, was appointed Marketing Officer, having been previously employed as Administrator during Kate Connor's maternity leave. The Trust also appointed Mrs. Maggy Barnes, FMAAT, as Accounting Technician, and Dr. John Newby, BSc(Hons), PhD, as Information Officer.

3.8 Voluntary Workers:

The Trustees are very appreciative of the work carried out by numerous volunteers throughout the United Kingdom and the Republic of Ireland in organising fundraising events. There are also many people who have had a major role in the background preparing the Conferences, BCRT Newsletter, Awareness Week and Media coverage.

In particular, the Trustees would like to thank Rosalyn Francis for her work as Clerk to the Trustees, and in her preparation of minutes and other documentation for Trustees' meetings, and contact with the Charity Commission, the Trusts' legal and accounting advisors, and supporting the Chairman with clerical work and research.

Also, the Trustees thank Alan Johnston for his work as Website Manager, particularly his vigilance in ensuring that the website is monitored, regularly refreshed, is compliant, is informative and is user friendly. The BCRT Website is highly regarded by other organizations, particularly in the way new stories and events are introduced, together with offering appropriate links to other websites.

Finally, the Trustees would like to express their thanks to Tabitha Hazeldine for her continued voluntary work in the office, together with Sadie Edwards; Barry Segelman; Charnjit Bahia; Neha Ladara and Zsofia Huber. All have been of great assistance in both the general and specific running of campaigns and events.

3.9 Human Resources Consultancy:

Abacus HR Ltd. continues to be the Trust's Human Resources Consultants. The Board thanks Gillian Pilcher for her continuing hard work in liaising with the Company on the Trustees' behalf. As a result, several new Policies have been developed and implemented.

3.10 Professional Advisors:

The Trustees were pleased to re-appoint as their Independent Examiner, Mr. C. J. Darwin, ACA, of Messrs. Thomas Coombs & Son, Chartered Accountants, and thank him for his scrutiny.

The Trustees also confirmed the continuing appointment of Brooke North LLP of Leeds as their Solicitors, and The Co-operative Bank as their Bankers. CAF Bank Ltd., have been appointed as additional Bankers.

3.11 General, Dedicated and Restricted Fund Accounts:

As part of maximizing the opportunities presented by different types of fundraising, the Trustees continue to offer 3 different types of accounts.

General Accounts are where the bulk of donations are placed, including those from 4 of the 6 Related Parties listed above (see paragraph 5.3).

Dedicated Accounts are funds which have been opened in memory of an individual, usually by bereaved family and friends. Not only do they allow their loved one's name to be remembered within the Bone Cancer Research Trust, they also can be used for local fundraising and raising awareness.

Restricted Accounts are very similar to Dedicated Accounts in that they are in the names of a loved one, but they may be restricted for a specific purpose, for example, to be ring-fenced for a particular aspect of research.

As at 30th. June 2010, the spread over the 3 types of account was as follows:-

General Accounts	Dedicated Accounts	Restricted Accounts
Adam Dealey Foundation for Ewing's Sarcoma	Guy Francis Bone Cancer Research Fund	Family & Friends of Krystle Smith (Ewing's Sarcoma)
Anthony Pilcher Bone Cancer Trust	Family & Friends of Jennifer Carvell	The Rhodri Jones Appeal (Osteosarcoma)
Blathnaid Foley Trust	Family & Friends of Kenny McCabe	Family & Friends of Hilary Lawler (Ewing's Sarcoma)
Christopher Hardman Osteosarcoma Research Trust	Family & Friends of Joseph Wright	Family & Friends of Nicola Curran (Ewing's Sarcoma)
General donations & other income	Matt's Beacon Fund	Vera (Kim) Penfold (Ewing's Sarcoma)
	Adam Panther Fund	Frognall Trust (Primary Bone Cancer)
	Daniel Round Fund	Seyhan and Memit Ali (Ewing's Sarcoma)
	Paul Gavin Fund	Takeda UK (Research Strategy Meeting)
	Nick Pollard Fund	
	Alex Albiston	

4.0 LINKS WITH OTHER ORGANISATIONS:

4.1 National Alliance of Childhood Cancer Parent Organisations (NACCPO) (RCN 1090871):

As Chairman of Trustees, Michael Francis represents the Trust on the National Executive Committee of NACCPO. This umbrella organisation has direct access to both national and international institutions who are leaders in the development and administration of research, health and support services for all cancers affecting children, teenagers and young adults.

Roger Paul and Ros Francis represented the Trust at the NACCPO Annual General Meeting (Oxford : 18th. June 2010). The BCRT display stand formed part of the conference exhibition.

4.2 British Sarcoma Group – 5th. Annual Conference (London – February 2010):

BCRT has attended all 5 Conferences (the other 4 being in Birmingham, Manchester, Sheffield & Glasgow), where the Trust has taken the opportunity to mount a display of its work. This year, the Trust was represented by Lauren Heslop.

4.3 Sarcoma UK:

The Trust continues its dialogue with Sarcoma UK, and looks forward to further collaborative working on projects of mutual interest including NICE Appraisals; the National Sarcoma Register; and the British Sarcoma Group Conference in February 2011 in Newcastle-upon-Tyne.

4.4 National Institute for Health and Clinical Excellence (NICE):

The Trust continues to provide evidence to the NICE Technical Appraisal Process during the Committee's consideration of the ultra orphan drug *Mifamurtide (MEPACT)*.

4.5 National Sarcoma Register Steering Group (NSRSG) (West Midlands Cancer Intelligence Group - WMCIG):

The Trust continued to contribute to the work of the Steering Group in its consideration of the four key areas which have been identified in relation to the Sarcoma Register:- As Breast Cancer can develop into a secondary "Breast Cancer in the Bone", the link is very pertinent.

Four key areas have been identified in relation to the Sarcoma Register:-

The need for better information, based on collecting the right data to improve outcomes.

The need for information to inform the commissioning of sarcoma services.

Development of the Sarcoma Register needs to be joined up with other initiatives in relation to sarcoma services such as the Map of Medicine initiative.

Through the NHS Standard Contract for Acute Services, the electronic transfer to cancer registries of the national cancer registration data set and multi-disciplinary team (MDT) meeting data will be mandatory requirements from NHS Hospital Trusts by 2011.

The Trust's representatives are Michael Francis and Hannah Millington.

Robert Grimer is the Steering Group Chairman. Jeremy Whelan is also a member of the Group. There are 2 other Patient Representatives from Sarcoma UK (Guy Sidford and Terri Johnson) with whom BCRT are working closely.

Towards the end of the year, the Department of Health confirmed that the Steering Group was to be reformed as the NCIN Sarcoma Site-Specific Clinical Reference Group, with the Trust retaining its representation.

4.6 Teenage Cancer Trust (TCT) (RCN 1062559):

The Trust is now engaged in a much closer working relationship with TCT, including support for their "Where's Your Sense Of Tumour?" event for teenage patients. Also, the possibility of joint project funding is being investigated.

5.0 ACHIEVEMENTS AND PERFORMANCE:

The Trust continues to focus on the development of fundraising opportunities, whilst widening its network base of Patients and Supporters, in support of its core object – funding medical research and improving patient outcomes.

5.1 Research Applications and Grants:

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

During the year 2006/07 the first 2 Research Grants were awarded. One of these is now published research and a synopsis appeared in the Trust's Spring 2009 Newsletter, which is reproduced on the BCRT Website. A 2nd. project from the University of Newcastle on "*Molecular Mechanisms*" has been published and, again, a synopsis appears in the Autumn 2009 Newsletter. By June 2010, some 18 Research Projects & 4 Research Conferences have been approved for funding. Details of all the Projects are set out below:

PROJECT / CONFERENCE				
Research Grant / Conference Award				
BCRT Year	Grant Round Closing Date	Description	Recipient / Beneficiary	Value £
2006/07		International Consensus Meeting on Local Control of Ewing's Sarcoma at The Belfry, West Midlands. (26 th . & 27 th . March 2007) & Support.	67 delegates from 11 countries throughout Europe & North America.	17,406
	1 st . Round 10 th . July 2006	An Epidemiological Study of Bone Tumours in Children and Young Adults.	Dr. Richard McNally Institute of Health and Society, University of Newcastle. <i>To start on 18th. June 2007 and finish 11th. July 2008 (13 months). Target date for publication January 2009.</i>	29,985
		The Development of Clinical Protocols for Ewing's Sarcoma Treatment Using Gene Transfer of T-Cell Receptors.	Dr. John Anderson Unit of Molecular Haematology & Cancer Biology, Institute of Child Health, Great Ormond Street Children's Hospital, London. <i>To start on 1st. October 2006 and finish on 31 March 2010 (42 months).</i>	34,500
		TOTAL FOR CONFIRMED GRANTS/AWARDS & SUPPORT : 1st, July 2006 to 30th, June 2007		81,891
2007/08	2 nd . Round 19 th . March 2007	Cancer stem cells in Osteosarcoma: potential for development of new prognostic markers and treatment.	Professor Adrienne Flanagan Royal National Orthopaedic Hospital, Middlesex. <i>To start on 1st. October 2007 and finish on 30th. September 2010 (36 months).</i>	28,800
		Identifying a novel role for deregulated Fibroblast Growth Factor Receptor Signalling in the growth control of human Osteosarcoma cells.	Dr. Agamemnon Grioriadis King's College, London. <i>To start 1st. October 2007 and finish on 30th. September 2008 (12 months).</i>	29,720
		A pilot pharmacogenomic study of the influence of cytotoxic metabolising gene polymorphisms on toxicity and outcome in respectable Osteosarcoma.	Dr. Rachael Windsor, University College Hospital, London. <i>To start on 4th. November 2007 and finish on 31st. October 2008 (12 months).</i>	30,000
	3 rd . Round 20 th .	Effects of hypoxia on growth, apoptosis and angiogenic capacity of Osteosarcoma and Ewing's Sarcoma cells;	Professor Nicholas Athanasou and Dr. Helen Knowles,	27,213

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

	October 2007	regulation by Hypoxia-inducible Factor.	University of Oxford. 1 st . April 2008 to 31 st . March 2010 (24 months)	
		Molecular mechanisms of organ-specific Ewing's Sarcoma metastasis.	Professor Josef Vormoor, Northern Institute for Cancer Research, University of Newcastle. To start on 1 st . August 2008 and finish on 31 st . July 2009 (12 months).	31,772
		Environmental contributions to the aetiology of bone tumours in young people: small area analyses.	Dr. Richard McNally Institute of Health and Society, University of Newcastle. To start on 1 st . October 2008 and finish on 30 th . September 2009 (12 months).	30,601
		1 st . Patients' and Supporters' Conference at the Leicester Hilton Hotel. (14 th . July 2007); and 2 nd . Patients' and Supporters' Conference at the Leicester Hilton Hotel. (28 th . June 2008).	1 st . Conference : 99 attendees 2 nd . Conference : 93 attendees	3,394 3,468
		1st. Newsletter (Autumn 2007) 2 nd . Newsletter (Spring 2008) 1st. Bone Cancer Awareness Week (June 2008) & Support		16,787
		TOTAL FOR CONFIRMED GRANTS/AWARDS & SUPPORT : 1st. July 2007 to 30th. June 2008		201,755
	4 th . Round 13 th . September 2008	A Pilot Study of the aetiology and genetics of bone tumours in children, teenagers and young adults	Professor Jillian Birch Royal Manchester Children's Hospital, University of Manchester To start on 1 st . January 2010 and finish on 30 th . June 2011 (18 months)	47,555
		The role of tumour-associated macrophages in the anti-osteosarcoma effects of bisphosphonates	Dr. Anke Jozefien Roelofs and Professor Michael John Rogers. University of Aberdeen. To start 1st. February 2009 and finish on 31 January 2010 (11 months)	30,829
		Investigating the combination of fenretinide and TRAIL receptor agonists in ESFT	Professor Susan Burchill Candlelighter's Children's Cancer Research Laboratory, Leeds Institute of Molecular Medicine, St. James's University Hospital, University of Leeds. To start on 1 st . April 2009 and finish on 31 st . March 2010 (12 months)	49,591
		Targeting FGF receptor signalling for the treatment of osteosarcoma	Dr. Agamemnon Grigoriadis Kings College, London To start on 1 st . June 2009 and finish on 31 st . December 2009 (7 months)	29,720

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

		A Pilot pharmacogenomic study of the influence of cytotoxic metabolising gene polymorphisms on toxicity and outcome in resectable osteosarcoma. PROJECT 2	Dr. Rachel Windsor University College Hospital, London <i>To start on 1st. December 2008 and finish on 30th. November 2009 (12 months)</i>	41,956
		3 rd . Patients' and Supporters' Conference at Sopwell House, St. Albans, Herts., (27 th . June 2009).	117 attendees	6,291
		3 rd . Newsletter (Autumn 2008) 4 th . Newsletter (Spring 2009) 2nd. Bone Cancer Awareness Week (June 2008) & Support		9,837
		TOTAL FOR CONFIRMED GRANTS/AWARDS & SUPPORT : 1st, July 2008 to 30th, June 2009		215,779
		3 YEAR TOTAL 1st. July 2006 to 30th. June 2009		499,425
	5 th . Round Autumn 2009	Overcoming the challenge of studying telomerase biology in clinical samples; towards understanding tumour heterogeneity, telomerase and clinical significance in ESFT.	Professor Susan Burchill Candlelighter's Children's Cancer Research Laboratory, Leeds Institute of Molecular Medicine, St. James's University Hospital, <i>To start on 1st January 2010 and finish on 31st. December 2010 (12 months)</i>	39,026
		Investigation of functional inhibition of STAT3 in Ewing's Sarcoma family tumours.	Dr. John Anderson, University College, London. <i>To start on 20th November 2009 and finish on 19th April 2011 (18 months)</i>	17,500
		Analysis of 3D mesenchymal stem cell-induced cytotoxicity in Osteosarcoma and Ewing's Sarcoma cell lines.	Dr. P. Genever, University of York. <i>To start on 1st January 2010 and finish on 31st. December 2010 (12 months)</i>	28,315
		An assessment of the PARP inhibitor AG-014699 as a chemo potentiating agent and novel therapy in Ewing's Sarcoma	Professor Curtin & Dr. Wilkinson, University of Newcastle/ <i>To start on 1st March 2010 and finish on 30th September 2010 (7 months)</i>	29,595
		Targeting gene therapy to primary bone cancers using novel delivery of RNA interference by attenuated bacteria.	Dr. T. Coughlan, University of Nottingham. <i>To start on 12th July 2010 and finish on 11th July 2011 (12 months)</i>	48,072
			J Vormoor underspend	-4835
			R McNally underspend	-885

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

		Research Conference, Leeds.		4,071
		5 th . Newsletter (Autumn 2009)		2,966
		6 th . Newsletter (Spring 2010)		
		TOTAL FOR CONFIRMED GRANTS/AWARDS & SUPPORT : 1st. July 2009 to 30th. June 2010		169,545
		4 YEAR TOTAL July 2006 to 30th. June 2010		668,970

Applications for the 6th. Round of Research Grants closed in Autumn 2009 with 5 further projects being approved, totalling £162,508.

The Trustees are very aware of the important and considerable contribution to the advancement of research into Ewing's Sarcoma made some 7 years before the foundation of the Bone Cancer Research Trust by John and Marian Dealey – through the Adam Dealey Foundation for Ewing's Sarcoma, in memory of their son, and, latterly, the fund raising by Patricia and Christopher Smith in the Republic of Ireland, in memory of their daughter Krystle, who was also diagnosed with Ewing's Sarcoma. These are set out in Appendix C.

5.2 Promotional Activity:

The Trustees are pleased to report a continuing and expanding level of activity across the whole spectrum of promotional activity, resulting in accelerated income growth and active participation by Patients and Supporters alike.

5.3 Autumn 2009 and Spring 2010 BCRT Newsletters:

The Trustees realise that good communications is paramount to attaining and maintaining contact with all those interested in the work of the Trust. But different customer groups – patients, former patients, families, friends, medical practitioners – will have different interests. In an attempt to cover all these interests, a pilot Newsletter was published in the Autumn 2007. It highlighted the success of the 1st. Patients' and Supporters' Conference with articles about the Speakers and the Discussion Groups; gave a full report on the International Consensus Meeting for medical practitioners; outlined the research being undertaken at University College Hospital, London (one of the Trust's first research grant awards); and reported on recent fundraising events, together with news of events being planned. The circulation included personal mail shots, as well as bulk mailings into hospitals and clinics.

It was received with warm approval giving the Trustees the confidence to launch a second Newsletter in Spring 2008.

The 3rd. Newsletter (Autumn 2008) reported on the June 2008 conference and the development of the National Sarcoma Register, plus an update on research projects and patients' personal experiences. The wide range of fundraising activities was also reported on.

The 4th. Newsletter (Spring 2009) concentrated on "*Getting active after treatment*" with contributions from BCRT Patron & Paralympic gold medallist Marc Woods; BCRT Trustee and England parafootballer Nick Bones, plus Paralympic swimming hopeful Laurence Whiteley. The Trust's first published research paper from Dr. Richard McNally of the University of Newcastle was featured, as was the NICE Appraisal Committee meeting on the breakthrough drug *Mifamurtide (MEPACT)*.

Newsletter 5 (Autumn 2009), gave a synopsis of the 2nd piece of published research as the result of BCRT funding., together with a major feature on “*Rehabilitation – what the future holds for prosthetics and endo-prosthetic replacement with physio*”.

The 6th. Newsletter (Spring 2010) highlighted the further work the Trust is undertaking in giving evidence to the NICE Technical Appraisal Committee for their consideration of *Mifamurtide (MEPACT)*. Also, a comprehensive map of the UK showing where the Trust’s funded research is taking place, plus an article in preparation of the Trust’s campaign in Ireland.

5.4 BCRT in Ireland:

During the year, BCRT in Ireland was launched with the intension of a full roll-out in September 2010.. This will include a specific section on the BCRT website.

5.5 Some of the many Fundraising Events in 2009/10:

The Trustees have been overwhelmed by the number and variety of events organised by the Trust’s supporters. These are some of the events – and apologies for any that have not been included here:-

A walk around the Swinsty Reservoirs, Harrogate : Reading Half-Marathon : Cycling from Land’s End to John O’Groat’s : Great Runs in Manchester, Newcastle, Edinburgh & Portsmouth : Flora London Marathon : Climing Mount Kilimanjaro : London Royal Parks Half-Marathon : Run For All in Leeds & York : Tractor Drive from Gloucester to Bolton Abbey (North Yorkshire) : Ironman – Switzerland : Chess Valley Walk : Rutland Water Cycle Challenge : Football Tournaments in Leeds & Hull : Parbold Hill Race : Asian Ball, Garden Party & Street Party : London to Paris Cycle Challenge : Fashion Show : and numerous coffee mornings, school collections and other fun things!!!Many, many thanks.

5.6 BCRT Merchandising:

The Trust now offers a range of promotional merchandise including Christmas cards; sweatshirts and T-shirts, both with the BCRT logo; enamelled badges; car stickers and several books written by BCRT supporters.

5.7 Development of the Website and other electronic forms of communication:

The World Wide Web offers unbounded opportunities for information sourcing and communication. The continuing development and maintenance of the Trust’s website is regarded as a vital tool in staying in touch with other organisations and with the Trust’s supporters; together with providing information for all those wishing to find out about Primary Bone Cancer or to seek the Trust’s support.

As Primary Bone Cancer is predominantly a young person’s cancer, creating the opportunities to embrace electronic technology which, they in particular, are used to is seen as a high priority. The Trustees have therefore encouraged new and innovative ideas including:

- www.justgiving.com (linking to all fundraising events by individual supporters : also generates Gift Aid).
- www.everyclick.com (providing a home page which generates income every time a site is sought).
- www.theweatherlottery.com (a fun lottery for supporters).
- www.nochex.com (for BCRT online merchandise shopping).
- www.health.groups.yahoo.com (providing 2 online Forums – one specifically for patients).
- www.bonecancerresearch.org.uk/links_blog.sctml (a patients’ blog crèche).
- www.bonecancerresearch.org.uk/links_org.shtml (reciprocal links to other organisations).
- www.facebook.com (social networking).
- www.twitter.com (cyber tracking)

5.8 Looking to the Future:

The Trustees look forward to the expansion of the Trust's activities in the next year. The Trustees are looking at their internal organisation and have established a number of specific committees – Strategic Planning : Finance : Fundraising : Management : Ireland : Campaigning & Marketing : Support : and Research & Information. In addition, and with the generous assistance of Messrs. Lane, Earl, Cox, the Trust is undertaking a rebranding of the organisation including website presentation, literature, public relations, campaigning strategy and overall promotion. This is to be launch at the Trust's 3rd Conference & Awareness Week in October 2010..

The Trustees will look to continue their funding of quality research projects, and will consider carefully any increase in the baseline level of funding of £30,000 per project.

Consideration will also be given to attracting further expertise to the Board, especially in the areas of financial investment and management, and medical practice.

6.0 FINANCIAL REVIEW:

The Financial Statements comply with the Statement of Recommended Practice "Accounting and Reporting by Charities" (SORP 2005) issued in March 2005, and the Trust Deed.

The financial results of the Charity are shown in the annexed Financial Statements. The net assets of the Charity are £635,863 (2009: £458,932) and the Trustees consider that, at the date of this Report, the financial position of the Charity is sound.

The Trustees are pleased to report commitment to charitable activities, including support costs, for 2009/10 of £225,515 (2009: £223,231), of which £157,238 has been committed to the award of approved Research Grants (2008: £178,106).

Gross receipts for the financial year are £494,666 (2008: £477,653). Since the foundation of the Trust on 15th. December 2005, £1,644,666 has been raised of which £668,970 has been spent or is committed to charitable activities.

6.1 Principle Funding Sources:

In 2009/10, the principal funding of the Charity continued to originate from the Founding Groups. Whilst these Groups still continue to be an important funding source, new sources are now making a major contribution to the financial strength and stability of the Charity.

6.2 Charity Reserves:

The Charity maintains sufficient reserves in order to enable the Charity to meet its objectives as stated above. The reserves of the Charity are continually monitored and reviewed within the context of the funds required to fulfil the objectives of the Charity.

6.3 Investment Policy:

There are no restrictions on the Charity's power to invest. At present, the funds of the Charity are held in current and deposit bank accounts. The Trustees consider this is the most appropriate form of investment at this time, given the nature of the Trust involving awarding grants and funding each year. Accordingly, the Trustees have no formal ethical policy on investments held by the Charity.

6.4 Donations:

Any donations, large or small, will help to fund research into Primary Bone Cancer and, hopefully, save young lives in the future. Anyone wishing to make one-off donations or set-up a regular donation to the Charity should contact the Head of Fundraising at the Trust's Fundraising & Administration Office. Cheques should be made payable to "Bone Cancer Research Trust". Donations can also be made via www.justgiving.com, and some events can be sponsored in the same way. Further information regarding donations can be obtained by e-mailing donations@bonecancerresearch.org.uk.

7.0 PLANS FOR FUTURE PERIODS:

The Trustees plan to continue the activities of the Charity in a similar manner as those of the previous year, through the Fundraising and Administration Office in Leeds.

Approved by the Board of Trustees on

and signed on its behalf by:-

ROGER PAUL

Chairman of Trustees

PATRICK HARDMAN

Trustee and Treasurer

8.0 FINANCIAL STATEMENT:

The Trustees are responsible for preparing the Annual Report and the Financial Statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Law applicable to charities in England & Wales requires the Trustees to prepare Financial Statements for each financial year, which give a true and fair view of the Charity's financial activities during the year, and of its financial position at the end of the year. In preparing these Financial Statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping accounting records that disclose with reasonable accuracy the financial position of the Charity, and which enable them to ensure that the financial statements comply with the Charities Act 1993, the Charity (Accounts Reports) Regulations 2008, and Trust Deed. They are also responsible for safeguarding the assets of the Charity, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

ROGER PAUL

Chairman of Trustees

PATRICK HARDMAN

Trustee and Treasurer

Date:

9.0 INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BONE CANCER RESEARCH TRUST:

I report on the Financial Statements of the Charity for the year ended 30th June 2010, which are set out on pages 23 to 35.

9.1 Respective responsibilities of Trustees and Examiner: The Charity's Trustees consider that an audit is not required for this year under section 43(2) of the Charities Act 1993 (the Act), and that an Independent Examination is needed. The charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of the Institute of Chartered Accountants in England & Wales. It is my responsibility to:

- examine the Accounts (under section 43 of The Act);
- follow the procedures laid down in the General Directions given by the Charity Commissioners (under section 43(7)(b) of the Act);
- state whether particular matters have come to my attention.

9.2 Basis of Independent Examiner's Report: My examination was carried out in accordance with General Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the Accounts presented with those records. It also includes consideration of any unusual items or disclosures in the Accounts, and the seeking of explanations from you as Trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, I do not express an audit opinion on the view given by the Accounts.

9.3 Independent Examiner's Statement: In connection with my Examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that, in any material respect, the Trustees have not met the requirement to ensure that:
 - proper accounting records are kept in accordance with section 41 of the Act; and
 - Accounts are prepared which agree with the accounting records and comply with the accounting requirements of the Act
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Financial Statements to be reached.

Mr C.J. Darwin ACA

Thomas Coombs & Son

Chartered Accountants

Century House, 29 Clarendon Road, Leeds LS2 9PG

Date :

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

10.0 STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30TH JUNE 2010:

	Notes	Unrestricted 2010 £	Restricted 2010 £	Total 2010 £	Total 2009 £
INCOME & EXPENDITURE:					
Income Resources from generated funds					
<i>Voluntary income:</i>					
Grants and donations	2	198,152	5,424	203,576	191,498
Investment income		5,088	-	5,088	13,660
<i>Activities for generating funds:</i>					
Event income		274,790	8,920	283,710	268,270
Other trading income		2,292	-	2,292	4,225
Total Income Resources		480,322	14,344	494,666	477,653
Resources Expended					
Costs of generating funds	3	76,716	3,000	79,716	97,871
Charitable activities					
Grants awarded and direct costs	4	150,195	13,609	163,804	198,406
Support costs	4	61,711	-	61,711	24,825
Governance costs	5	12,504	-	12,504	6,760
Total Resources Expended		301,126	16,609	317,735	327,862
NET INCOMING (OUTGOING) RESOURCES FOR THE YEAR		179,196	(2,265)	176,931	149,791
NET MOVEMENT IN FUNDS		179,176	(2,265)	176,931	149,791
Reconciliation of funds					
Balances brought forward at 1 st July 2009		447,747	11,185	458,932	309,141
BALANCES CARRIED FORWARD AT 30TH JUNE 2010		626,943	8,920	635,863	458,932

All amounts relate to continuing activities.

All recognised gains and losses are included in the Statement of Financial Activities.

The notes on pages 25 to 35 form part of these Financial Statements.

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

11.0 BALANCE SHEET AT 30TH JUNE 2010:

	Notes	Unrestricted 2010 £	Restricted 2010 £	Total 2010 £	Total 2009 £
Fixed Assets	7	2,651	-	2,651	3,440
Current Assets					
Stock		2,002	-	2,002	-
Debtors:					
Gift aid recoverable		2,235	-	2,235	7,897
Accrued income		126	-	126	11,224
Prepayments		3,312	-	3,312	3,392
Cash at Bank		858,597	8,920	867,517	702,031
		<hr/>	<hr/>	<hr/>	<hr/>
		866,272	8,920	875,192	724,544
Liabilities: amounts falling due within one year	8	(237,974)	-	(237,974)	(259,252)
		<hr/>	<hr/>	<hr/>	<hr/>
Net Current Assets		628,298	8,920	637,218	465,292
		<hr/>	<hr/>	<hr/>	<hr/>
Total Assets less Current Liabilities		630,949	8,920	639,869	468,732
Liabilities: amounts falling due after one year	9	(4,006)	-	(4,006)	(9,800)
		<hr/>	<hr/>	<hr/>	<hr/>
Net Assets		626,943	8,920	635,863	458,932
		<hr/>	<hr/>	<hr/>	<hr/>
Funds					
Unrestricted		626,943	-	626,943	447,747
Restricted	11	-	8,920	8,920	11,185
		<hr/>	<hr/>	<hr/>	<hr/>
Total Funds		626,943	8,920	635,863	458,932
		<hr/>	<hr/>	<hr/>	<hr/>

Approved by the Board of Trustees on

and signed on its behalf by:

ROGER PAUL
 Chairman of Trustees

PATRICK HARDMAN
 Trustee and Treasurer

The notes on pages 25 to 35 form part of these Financial Statements.

12.0 NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH JUNE 2010:

1 Accounting Policies:

Accounting Convention:

The Accounts are prepared under the historical cost convention. They have been drawn up to comply with the Statement of Recommended Practice on "Accounting and Reporting by Charities" (SORP 2005) issued in March 2005 and applicable UK Accounting Standards and the Charities Act 1993.

Income:

All incoming resources are recognised once the charity has entitlement to the resources, it is certain that the resources will be received and the monetary value of incoming resources can be measured with sufficient reliability.

- (i) Grants receivable:
Grants receivable are credited to the income and expenditure account on an accruals basis with grants received for specific purposes treated as restricted income.
- (ii) Donations and Gifts:
All monetary donations and gifts are credited to the income and expenditure account in the year of receipt. No value is attributed to donations in kind and these are not included in the income and expenditure account.
- (iii) Covenanted income:
Donations under deed of covenant together with the associated income tax recoveries are credited to the income and expenditure account when the covenant payments are receivable. Covenant payments which are due but have not been paid at the Balance Sheet date are shown as debtors.

Resources expended:

Liabilities are recognised as resources expended as soon as there is a legal or constructive obligation committing the charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

(a) Grants payable:

Grants payable are payments made to third parties in the furtherance of the charitable objectives of the Trust. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and any condition attaching to the grant is outside of the control of the Trust.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

(b) Irrecoverable VAT

Irrecoverable VAT is charged against the category of resources expended for which it was incurred.

(c) Charitable activities

Costs of charitable activities include grants made and an apportionment of overhead and support costs.

(d) Governance costs

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to external inspection and legal fees together with an apportionment of overhead and support costs.

Fund accounting:

(i) Restricted Funds:

The restricted funds (if any) are funds which have been raised for, and their use restricted to, a specific purpose, or donations subject to donor imposed conditions.

(ii) Dedicated Funds:

Designated funds (if any) are funds set aside out of general funds and designated for specific purposes by the Trustees.

(iii) Unrestricted Funds:

The unrestricted funds consist of those funds which the Charity may use in furtherance of its charitable objectives at the discretion of the Trustees.

Taxation:

The Trust is a Registered Charity and therefore is not liable for income tax or corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to Registered Charities.

Fixed assets and depreciation:

Fixed assets are capitalised at their cost value. Depreciation is provided on all tangible fixed assets at rates calculated to write off the cost, less estimated residual value, of the assets over their expected useful lives. Depreciation is currently provided on the fixtures, fittings and office equipment at the principal rate of 25% per annum on a straight line basis (previously 25% per annum on a reducing balance basis).

Stocks:

Stocks are valued at the lower of cost and net realisable value. Cost is based on the cost of purchase on a first in, first out basis. Net realisable value is based on estimated selling price less additional costs to disposal.

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

2. Grants and Donations:

	Unrestricted 2010 £	Restricted 2010 £	Total 2010 £	Total 2009 £
Adam Dealey Foundation for Ewing's Sarcoma	15,050	-	15,050	22,000
Adam Panther	6,202	-	6,202	7,000
Blathnaid Foley Trust	22,123	-	22,123	22,515
Daniel Round Fund	397	-	397	1,141
Family & Friends of Jennifer Carvell	1,424	-	1,424	5,636
Family & Friends of Joseph Wright	750	-	750	958
Family & Friends of Kenny McCabe	835	-	835	978
Guy Francis Bone Cancer Research Fund	4,946	-	4,946	12,058
Nick Pollard Fund	2,631	-	2,631	6,404
Paul Gavin Fund	11,133	-	11,133	9,406
Stephanie McCartney	-	-	-	215
CHORF – The Christopher Hardman Osteosarcoma Research Fund	30,000	-	30,000	-
Matt's Beacon Fund	123	-	123	-
Alex Albiston	5,745	-	5,745	-
Other general donations	96,793	-	96,793	94,822
Restricted Accounts:				
Family & Friends of Krystle Smith	-	279	279	6,942
Family & Friends of Nicola Curran	-	-	-	1,423
Vera (Kim) Penfold	-	645	645	-
Frognall Trust	-	1,500	1,500	-
Takeda UK	-	3,000	3,000	-
	<hr/>	<hr/>	<hr/>	<hr/>
	198,152	5,424	203,576	191,498
	<hr/>	<hr/>	<hr/>	<hr/>

3 Cost of Generating Funds:	2010	2009
	£	£
Events costs	23,752	41,232
Other trading costs	3,166	4,936
Staff costs	37,661	39,050
Other fundraising costs	15,137	12,653
	79,716	97,871
	£	£
4. Charitable Activities:		
Grants awarded:		
Professor Jillian Birch, Paediatric & Familial Cancer Research Group Royal Manchester Children's Hospital	-	47,555
<i>"A Pilot study of the aetiology and genetics of bone tumours in Children, teenagers and young adults"</i>		
Dr. Roelofs & Professor Rogers, The University of Aberdeen	-	30,829
<i>"The role of tumour-associated macrophages in the anti-osteosarcoma effects of bisphosphonates"</i>		
Professor Susan Burchill, Candlelighter's Children's Cancer Research Lab St James's University Hospital	-	45,591
<i>"Investigating the combination of fenretinide and TRAIL receptor agonists in ESFT"</i>		
<i>"Overcoming the challenge of studying telomerase biology in clinical samples; towards understanding tumour heterogeneity, telomerase and clinical significance in ESFT."</i>	39,026	-
Dr. Richard McNally Institute of Health & Society, University of Newcastle	(885)	(3,351)
<i>"Environmental contributions to the aetiology of bone tumours in Young People: small area analyses"</i>		

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

Dr. Agamemnon Grigoriadis, Kings College, London	-	29,720
<i>"Targeting FGF receptor signalling for the treatment of osteosarcoma"</i>		
Dr. Rachel Windsor, University College Hospital, London	-	41,956
<i>"A pilot pharmacogenomic study of the influence of cytotoxic target and metabolising gene polymorphisms on toxicity and outcome in resectable osteosarcoma"</i>		
Dr. John Anderson, University College, London	17,500	-
<i>"Investigation of functional inhibition of STAT3 in Ewing's sarcoma family tumours."</i>		
Dr. P Genever, University of York, York	28,315	-
<i>"Analysis of 3D mesenchymal stem cell-induced cytotoxicity in osteosarcoma and Ewing's sarcoma cell lines."</i>		
Professor Curtin & Dr. Wilkinson, Newcastle University, Newcastle	29,595	-
<i>"An assessment of the PARP inhibitor AG-014699 as a chemo potentiating agent and novel therapy in Ewing's sarcoma."</i>		
Dr. T Coughlan, University of Nottingham, Nottingham	48,072	-
<i>"Targeting gene therapy to primary bone cancers using novel delivery of RNA interference by attenuated bacteria."</i>		
Professor J Vormoor	(4,385)	-
<i>"Molecular mechanisms of organ-specific Ewing's sarcoma metastasis."</i>		
	<hr/> 157,238	<hr/> 196,300
Conferences	-	6,291
Newsletters	2,966	(10,777)
Staff costs	3,600	6,592
	<hr/> <hr/> 163,804	<hr/> <hr/> 198,406

4. Charitable Activities (continued)

	2010	2009
	£	£
Support Costs:		
Premises costs	7,530	7,104
Telephone	1,117	2,213
Postage	1,993	3,165
Stationery and printing	1,683	1,071
Loss on disposal of fixed assets	244	-
Sundries	2,277	444
Depreciation	1,540	1,147
Staff costs	36,293	5,858
Recruitment and human resources costs	2,817	1,655
Travel and subsistence	6,217	2,168
	<hr/>	<hr/>
	61,711	24,825
	<hr/> <hr/>	<hr/> <hr/>

5. Governance Costs:

	2010	2009
	£	£
Meeting expenses	3,877	1,095
Independent examiners remuneration	3,260	3,260
Legal and professional costs	5,119	2,039
Staff costs	248	366
	<hr/>	<hr/>
	12,504	6,760
	<hr/> <hr/>	<hr/> <hr/>

6. Trustees and Staff Costs:

Staff costs:	2010	2009
	£	£
Wages and salaries	71,648	47,223
Employer's National Insurance	6,154	4,643
Total	<u>77,802</u>	<u>51,866</u>

Reimbursed expenses, which are all subject to the charity's processes of internal controls, do not form part of the remuneration and are not included above.

The Trustees received no remuneration. During the period, travel expenses of £1,593 were reimbursed to five trustees.

No employee earned more than £60,000 per annum.

The average number of employees (full and part time):

	2010	2009
	No.	No.
Permanent staff	5	2
Trustees	12	11
Total	<u>17</u>	<u>13</u>

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

7. Fixed Assets:

	Office Equipment	Computer Equipment	Total
Cost:			
As at 1 st July 2009	476	5,640	6,116
Additions	-	995	995
Disposals	-	(585)	(585)
As at 30 th June 2010	<u>476</u>	<u>6,050</u>	<u>6,526</u>
Depreciation:			
As at 1 st July 2009	208	2,468	2,676
Charged during the year	119	1,421	1,540
Eliminated on disposal	-	(341)	(341)
As at 30 th June 2010	<u>327</u>	<u>3,548</u>	<u>3,875</u>
Net Book Value:			
30 th June 2010	<u><u>149</u></u>	<u><u>2,502</u></u>	<u><u>2,651</u></u>
30 th June 2009	<u>268</u>	<u>3,172</u>	<u>3,440</u>

8. Liabilities: Amounts falling due within One Year:

	2010 £	2009 £
Grants awarded and related creditors	230,981	242,629
Accruals	3,200	3,452
Taxation & social security	2,094	236
Other creditors	1,699	12,935
	<u><u>237,974</u></u>	<u><u>259,252</u></u>

9. Liabilities: Amounts falling due after One Year:	2010	2009
	£	£
Grants awarded	4,006	9,800

10. Dedicated Funds:

Designated bank accounts have existed to enable individuals to raise funds for the Charity in an individual's name. For example, families and friends are able to raise money with regard to a person who has suffered from Bone Cancer.

The funds are not subject to restrictions and were previously classified as Dedicated Funds.

The Trustees are now recording these balances as part of the general fund but record the cumulative value of these contributions as at 30 June 2010 as follows:

Guy Francis Bone Cancer Research Fund	£133,561
Jennifer Carvell Fund	£19,558
Kenny McCabe Fund	£7,951
Joseph Wright Fund	£15,940
Daniel Round Fund	£1,991
Matt's Beacon Fund	£43,123
Adam Panther Fund	£13,202
Nick Pollard Fund	£9,035
Stephanie McCartney Fund	£215
Paul Gavin Fund	£20,539
Hilary Lawler Fund	£1,000
Alex Albiston Fund	£5,745

11. Other Restricted Income:

Seyhan and Memit Ali	£8,920
Vera (Kim) Penfold	£645
Nicola Curran	£1,423
Rhodri Jones Memorial Fund	£55,000

11. Restricted Funds:	Krystle Smith	The Rhodri Jones Appeal	Vera (Kim) Penfold	Frognall Trust	Seyhan & Memit Ali	Takeda UK
	£	£	£	£	£	£
Opening balance	2,924	8,261	-	-	-	-
Voluntary income:	-	-	-	-	-	-
Grants and donations	279	-	645	1,500	8,920	3,000
Total Incoming Resources For The Year	279	-	645	1,500	8,920	3,000
Expenditure:						
<i>Settlement of obligations for the following grants</i>						
Dr John Anderson, Institute of Child Health (Awarded 2007)	-	-	645	-	-	-
Prof. Josef Vormoor, Northern Institute for Cancer Research (Awarded 2008)	3,203	-	-	-	-	-
Dr Agamemnon Grigoriadis, Kings College (Awarded 2009)	-	8,261	-	-	-	-
Dr R McNally – Newcastle University (Awarded 2008)	-	-	-	1,500	-	-
Queens Hotel – Research strategy meeting	-	-	-	-	-	3,000
Total Expenditure For The Year	3,203	8,261	645	1,500	-	3,000
Closing balance	-	-	-	-	8,920	-

The Krystle Smith Restricted Fund represents monies restricted for research into Ewing's Sarcoma.

The Rhodri Jones Appeal represents funds raised by the Jones family for research into Osteosarcoma.

BONE CANCER RESEARCH TRUST.

Report of the Trustees and Financial Statements for the year ended 30th. June 2010.

The Vera (Kim) Penfold Restricted Fund represents monies restricted for research into Ewing's Sarcoma.

The Frognall Trust Restricted Fund represents monies restricted for research into primary bone cancer.

The Seyhan & Memit Ali Restricted Fund represents monies restricted for research into Ewing's Sarcoma.

The Takeda UK Restricted Fund represents monies restricted for a research strategy meeting.

APPENDIX A: HOW THE BONE CANCER RESEARCH TRUST CAME INTO BEING:

In September 2004, Dr. Ian Lewis, Consultant Paediatric & Adolescent Oncologist at St. James's University Hospital, Leeds, invited 5 families from Lewes (Sussex), Helston (Cornwall), Liverpool, Newcastle-upon-Tyne and York to a meeting to explore areas of mutual interest. All were bereaved families having lost a teenage daughter or son as a result of having the most common form of Primary Bone Cancer – Osteosarcoma. All the families had started raising funds in memory of their child but none had been able to find a charity dedicated to funding research into this type of cancer. Dr. Lewis explained that Primary Bone Cancers (PBCs) did not, in fact, attract extensive research funding from the National Health Service or the national cancer charities and, as a result, there was little research into the causes of PBCs, or into developing new treatments.

The families learnt that around 90% of all new cases of Osteosarcoma per annum were detected in children and teenagers, the peak age being between 15 - 20 years. The survival rate for Osteosarcoma beyond 5 years was 55%.

Four of the five families resolved to continue discussions to see if, by pooling their financial resources, a viable fund could be set up to kick start much needed research. By March 2005, a theme had been developed which saw any future Charitable Trust as being:-

“Devoted to promoting research into the causes and treatment of Primary Bone Cancer, and in particular of Osteosarcoma and Ewing’s Sarcoma.”

Further meetings took place and it became apparent that viability could be strengthened if contact was made with families of children and teenage patients of another PBC – Ewing’s Sarcoma. With Ewing’s Sarcoma, the age range was slightly different peaking between 10 – 20 years, with a survival rate beyond 5 years of some 60%. Together, new cases of Osteosarcoma and Ewing’s Sarcoma would number around 400 young people per annum in the United Kingdom. In addition, some research into Ewing’s Sarcoma had been identified, chiefly through the Adam Dealey Foundation for Ewing’s Sarcoma which had funded research projects since 1998.

Two more goals would be considered. All those participating in the discussions were from bereaved families. No consideration had been given to involving those patients undergoing treatment (and their families), or to patients who were now in remission. To address this, it was decided to seek someone from the latter category to be a Trustee, and consequently, in July 2005, Nick Bones joined the Working Party.

Further objectives were agreed. In addition to promoting research into “*causes and treatment*”, the Trust would back research into “*improving patient outcomes*”. Also, the Trust would look to “*provide information, support and, in the longer term, counselling services for those suffering from Primary Bone Cancer, and their families.*”. It was also realised that the appraisal and selection of suitable research projects could not be undertaken by the Founding Members as they were not appropriately qualified. It was decided that a Scientific Advisory Panel should be established, and Dr. Ian Lewis was invited to consider the scope, organisational structure and membership of the Panel. At the same time, thought was given to widening the appeal of the future Trust by inviting Medical Practitioners to participate in the Trust’s activities.

The Dealeys attended the Working Party in July 2005. They were in contact with another Ewing’s patient family in the Republic of Ireland (the family and friends of Krystle Smith) who came over to the Working Party’s September 2005 meeting. At this meeting, 9 families decided to formalise an alliance, and to establish a Charitable Trust.

The 9 Founding Members were:-

CHARITY OR GROUP	LOCATION	FAMILY
Adam Dealey Foundation for Ewing's Sarcoma	Hemel Hempstead, Hertfordshire	Adam was diagnosed with Ewing's Sarcoma, aged 9.
Anthony Pilcher Bone Cancer Trust (<i>Reg. Charity No. 1099337</i>)	Peacehaven, East Sussex	Anthony was diagnosed with Osteosarcoma, aged 14
Christopher Hardman Osteosarcoma Research Fund (<i>Reg. Charity No. 1111059</i>)	Wirral, Merseyside	Christopher was diagnosed with Osteosarcoma, aged 13
Guy Francis Bone Cancer Research Fund	York, North Yorkshire	Guy was diagnosed with Osteosarcoma, aged 17
Family & Friends of Krystle Smith	Arklow, County Wicklow, Republic of Ireland	Krystle was diagnosed with Ewing's Sarcoma, aged 17
Family & Friends of Emma Callar	Helston, Cornwall	Emma was diagnosed with Osteosarcoma, aged 14
Family & Friends of Stephanie McCartney	Keighley, West Yorkshire	Stephanie was diagnosed with Osteosarcoma, aged 13
Family & Friends of Joe Thompson	Kettering, Northamptonshire	Joe was diagnosed with Osteosarcoma, aged 11
Family & Friends of Jennifer Carvell	Liverpool, Merseyside	Jennifer was diagnosed with Osteosarcoma, aged 13

APPENDIX B : INITIAL STRUCTURE GOVERNANCE AND MANAGEMENT:

B.1 Governing Document:

The Trust became an Unincorporated Trust, constituted under a Trust Deed dated 15th. December 2005. On the 14th. March 2006 it became a Registered Charity, Number 1113276. The Trust Deed was signed by Nicholas Darren Bones, Gillian Anne Callar, John Dealey, Michael Brian Palmer Francis, Robert Grimer, Patrick Michael Hardman, Ian John Lewis, Deborah Alice McCarthy, Gillian Pilcher, and Patricia Smith.

B.2 Organisational Structure:

The Trustees must hold at least 4 Ordinary Meetings each year and agree the broad strategy and areas of activity of the Trust, including consideration of grant making, investment, reserves and risk management policies and performance.

B.3 First Trustees:

The first Trustees, in accordance with the Trust Deed, hold the office of Trustee for the following number of years:-

3 years	4 years	5 years
N. D. Bones R. Grimer	J. Dealey D.A.McCartney G. Pilcher	G. A. Callar M. B. P. Francis P. M. Hardman I. J. Lewis P. Smith

The First Trustees elected Michael Francis and John Dealey as Chairman and Deputy Chairman of Trustees respectively.

The background to each First Trustees is as follows:-

Nicholas Darren Bones	Former Osteosarcoma Patient
Gillian Anne Callar	Mother of Emma
John Dealey	Father of Adam
Michael Brian Palmer Francis	Father of Guy
Robert Grimer	Medical Practitioner
Patrick Michael Hardman	Father of Christopher
Ian John Lewis	Medical Practitioner
Deborah Alice McCartney	Mother of Stephanie
Gillian Pilcher	Mother of Anthony
Patricia Smith	Mother of Krystle

B.4 Scientific Advisory Panel (SAP):

In accordance with the wishes of the Founding Members, a Scientific Advisory Panel was established under the Chairmanship of Dr. Ian Lewis, to assist the Trustees in the award of Research Grants. The SAP consists of eminent Medical Practitioners, who are supported by a number of invited Specialist Advisors drawn from respected research centres throughout the United Kingdom.

The role of the SAP is to:-

- arrange and agree timescales for calls for research applications
- decide which Special Advisors (SA) should receive individual applications
- agree external peer reviewers with the SAs
- receive external peer review and recommendations from SAs
- meet to determine ranking and funding priority of applications, and make recommendations to Trustees

The first appointed members of the Scientific Advisory Panel were:-

Dr. I J. Lewis MB ChB FRCP FRCPCH.
Consultant Paediatric & Adolescent Oncologist, St. James's University Hospital, Leeds.

Mr. R. Grimer MB BS FRCS (Eng) FRCS (Edin) Orth.
Consultant Orthopaedic Surgeon, Royal Orthopaedic Hospital, Birmingham.

Dr. J. Whelan MD MB BS FRCP.
*Consultant Medical Oncologist and Clinical Director of Cancer Services,
Meyerstein Institute of Oncology, University College Hospital, London.*

B.5 Recruitment and Appointment of Trustees:

The Trust Deed requires the Board of Trustees to have at least 10 members. Apart from the first Trustees, every Trustee must be appointed by a resolution of the Trustees passed at a Special Meeting. On their appointment, each new Trustee is provided with at least a copy of the Trust Deed, and the Charity's latest Annual Report and Financial Statement of Accounts.

APPENDIX C : PRE-TRUST FOUNDATION RESEARCH PROJECTS:

Whilst their fundraising awards prior to 15th. December 2005 play no part in the records of the Trust, nonetheless the impartial Trustees wish to place on public record an account of the fundraising activities made by the Dealey and Smith families as a grateful acknowledgement of their considerable contribution to medical research into Ewing's Sarcoma.

First Round : 1998.

- *Basic fibroblast growth factor (bFGF) – induced apoptosis and fibroblast growth factor receptor (FGFr) expression in Ewing's Sarcoma.* Dr. Sue Burchill, University of Leeds. (£20,992).
- *Assessment of chromosomal abnormalities I Ewing's / PNET tumours by 24 colour FISH, colour banding and comparative genomic hybridisation.* Dr. Nick Coleman, University of Cambridge. (£10,000).

Second Round : 2000.

- *The role of novel FGFr3 variant in the development and behaviour of Ewing's Sarcoma.* Dr. Sue Burchill, University of Leeds. (£33,377).

Third Round : 2002.

- *RNA interference as a novel therapeutic tool against Ewing's Sarcoma / Primitive Neuroectodermal Tumours.*
Professor Chris Boshoff and Dr. Richard Frow, The Wolfson Institute for Biomedical Research, University College, London. (£20,000)

Fourth Round : 2004.

- *Developing a methodology to investigate international differences in presentation and outcome in patients with Ewing's Sarcoma.*
Dr. Ian Lewis, St. James's University Hospital, Leeds. (£25,000).

Fifth Round : 2005. In conjunction with the Family and Friends Of Krystle Smith.

- *Exploiting hypoxia and angiogenesis for therapeutic advantage in Ewing's Sarcoma family of tumours.* Dr. Sue Burchill, University of Leeds. (£24,516).
- *Two clinical trials of treosulfan in relapsed and advanced Ewing's Sarcoma.* Dr. Jeremy Whelan, University College London Hospitals. (£25,000).

These 7 Research Projects total £158,885.

Appendix D : An update on the Trustees of the Bone Cancer Research Trust.

Following the financial year end on 30th June 2010, two additional trustees were appointed on 11th September 2010, namely Sarah Dawson and Andrew Sheppard.

At the Annual General Meeting which was held on 26th November 2010, one trustee resigned and changes were made to the positions of Chairman and Deputy Chairman.

The full list of Trustees from that date are:-

Chairman - Roger Paul and Deputy Chairman - Patrick Hardman.

Other Trustees – Sarah Dawson, John Dealey, Fiona Foley, Craig Gerrand, Laura Horton, Ian Lewis, Gill Pilcher, Andrew Sheppard and Patricia Smith; the current number of Trustees totalling eleven